Title: Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?

URL Source: http://link.springer.com/article/10.1007/s11912-025-01704-z

Markdown Content:
## Abstract

### Purpose of Review

This review evaluates the scientific evidence for Ivermectin’s potential anticancer properties, an antiparasitic drug garnering interest for oncology applications. It assesses the gap between preclinical and clinical evidence and explores implications for healthcare communication based on current evidence.

### Recent Findings

Preclinical studies (in vitro and animal studies) demonstrate Ivermectin’s anticancer effects, including inhibition of cancer cell proliferation, induction of apoptosis, and modulation of signaling pathways (e.g., Wnt/β-catenin, Akt/mTOR) across various cancers. However, clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits. Observational studies and case reports highlight the risks of self-medication driven by social media touting Ivermectin’s unproven cancer benefits, which can lead to toxicity in oncology patients in some cases. The lack of clinical studies creates a critical translational gap between preclinical results and practical clinical application.

### Summary

Despite promising preclinical data, the absence of conclusive large-scale human clinical evidence limits Ivermectin’s utility in cancer treatment. Its affordability appeals in resource-limited settings, but ethical challenges arise from misinformation, which may lead patients to forgo proven therapies. Healthcare providers must communicate responsibly to counter misinformation and guide patients toward evidence-based interventions, while supporting rigorous clinical trials to bridge the preclinical-clinical gap.

## Access this article

[Log in via an institution](http://wayf.springernature.com/?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11912-025-01704-z)

## Subscribe and save

Springer+

from $39.99 /Month

*   Starting from 10 chapters or articles per month
*   Access and download chapters and articles from more than 300k books and 2,500 journals
*   Cancel anytime

[View plans](https://link.springer.com/product/springer-plus)

## Buy Now

Price excludes VAT (USA) 

 Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

**Fig.1**

![Image 1](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11912-025-01704-z/MediaObjects/11912_2025_1704_Fig1_HTML.jpg)

### Similar content being viewed by others

![Image 2](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1007%2Fs00280-020-04041-z/MediaObjects/280_2020_4041_Fig1_HTML.png)

![Image 3](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1007%2Fs11523-019-00678-w/MediaObjects/11523_2019_678_Fig1_HTML.png)

![Image 4](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1007%2Fs11523-022-00916-8/MediaObjects/11523_2022_916_Fig1_HTML.png)

## Data Availability

No datasets were generated or analysed during the current study.

## Code Availability

Not applicable.

## References

1.   Kositz C, et al. Broadening the range of use cases for ivermectin - a review of the evidence. Trans R Soc Trop Med Hyg. 2022;116(3):201–12.

[Article](https://doi.org/10.1093%2Ftrstmh%2Ftrab114)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34323283)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xoslaqs7s%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Broadening%20the%20range%20of%20use%20cases%20for%20ivermectin%20-%20a%20review%20of%20the%20evidence&journal=Trans%20R%20Soc%20Trop%20Med%20Hyg&doi=10.1093%2Ftrstmh%2Ftrab114&volume=116&issue=3&pages=201-212&publication_year=2022&author=Kositz%2CC)

2.   Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13–28.

[Article](https://doi.org/10.2183%2Fpjab.87.13)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21321478)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXkt1alsL4%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%2C%20%E2%80%98wonder%20drug%E2%80%99%20from%20Japan%3A%20the%20human%20use%20perspective&journal=Proc%20Jpn%20Acad%20Ser%20B%20Phys%20Biol%20Sci&doi=10.2183%2Fpjab.87.13&volume=87&issue=2&pages=13-28&publication_year=2011&author=Crump%2CA&author=%C5%8Cmura%2CS)

3.   Thylefors B, Alleman MM, Twum-Danso NA. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. Trop Med Int Health. 2008;13(5):689–96.

[Article](https://doi.org/10.1111%2Fj.1365-3156.2008.02049.x)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18419585)[CAS](http://link.springer.com/articles/cas-redirect/1:STN:280:DC%2BD1c3lvFCltg%3D%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Operational%20lessons%20from%2020%20years%20of%20the%20Mectizan%20Donation%20Program%20for%20the%20control%20of%20onchocerciasis&journal=Trop%20Med%20Int%20Health&doi=10.1111%2Fj.1365-3156.2008.02049.x&volume=13&issue=5&pages=689-696&publication_year=2008&author=Thylefors%2CB&author=Alleman%2CMM&author=Twum-Danso%2CNA)

4.   Kaur B, Blavo C, Parmar MS. Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy. Cureus. 2024;16(3):e56025.

[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38606261)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008553)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%3A%20a%20multifaceted%20drug%20with%20a%20potential%20beyond%20anti-parasitic%20therapy&journal=Cureus&volume=16&issue=3&publication_year=2024&author=Kaur%2CB&author=Blavo%2CC&author=Parmar%2CMS)

5.   Cully DF, et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature. 1994;371(6499):707–11.

[Article](https://doi.org/10.1038%2F371707a0)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7935817)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DyaK2MXhslSqsLw%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cloning%20of%20an%20avermectin-sensitive%20glutamate-gated%20chloride%20channel%20from%20Caenorhabditis%20elegans&journal=Nature&doi=10.1038%2F371707a0&volume=371&issue=6499&pages=707-711&publication_year=1994&author=Cully%2CDF)

6.   Suvarna V. Ivermectin: a critical review on characteristics, properties, and analytical methods. J AOAC Int. 2023;106(3):534–57.

[Article](https://doi.org/10.1093%2Fjaoacint%2Fqsad031)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36864616)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXhtVGjsL3F)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%3A%20a%20critical%20review%20on%20characteristics%2C%20properties%2C%20and%20analytical%20methods&journal=J%20AOAC%20Int&doi=10.1093%2Fjaoacint%2Fqsad031&volume=106&issue=3&pages=534-557&publication_year=2023&author=Suvarna%2CV)

7.   Zhou S, et al. Ivermectin has new application in inhibiting colorectal cancer cell growth. Front Pharmacol. 2021;12:717529.

[Article](https://doi.org/10.3389%2Ffphar.2021.717529)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34483925)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415024)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1ehsLnP)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20has%20new%20application%20in%20inhibiting%20colorectal%20cancer%20cell%20growth&journal=Front%20Pharmacol&doi=10.3389%2Ffphar.2021.717529&volume=12&publication_year=2021&author=Zhou%2CS)

8.   Tung CL, et al. Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells. Int J Med Sci. 2022;19(10):1567–75.

[Article](https://doi.org/10.7150%2Fijms.76623)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36185334)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515697)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXlt12mt7o%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20induces%20cell%20cycle%20arrest%20and%20caspase-dependent%20apoptosis%20in%20human%20urothelial%20carcinoma%20cells&journal=Int%20J%20Med%20Sci&doi=10.7150%2Fijms.76623&volume=19&issue=10&pages=1567-1575&publication_year=2022&author=Tung%2CCL)

9.   Lee DE, et al. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front Pharmacol. 2022;13:934746.

[Article](https://doi.org/10.3389%2Ffphar.2022.934746)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36091811)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459089)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB38XisFaku7bI)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20and%20gemcitabine%20combination%20treatment%20induces%20apoptosis%20of%20pancreatic%20cancer%20cells%20via%20mitochondrial%20dysfunction&journal=Front%20Pharmacol&doi=10.3389%2Ffphar.2022.934746&volume=13&publication_year=2022&author=Lee%2CDE)

10.   Rabben HL, et al. Computational drug repositioning and experimental validation of Ivermectin in treatment of gastric cancer. Front Pharmacol. 2021;12:625991.

[Article](https://doi.org/10.3389%2Ffphar.2021.625991)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33867984)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044519)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlWnurfN)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Computational%20drug%20repositioning%20and%20experimental%20validation%20of%20Ivermectin%20in%20treatment%20of%20gastric%20cancer&journal=Front%20Pharmacol&doi=10.3389%2Ffphar.2021.625991&volume=12&publication_year=2021&author=Rabben%2CHL)

11.   Jiang L, et al. Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway. Am J Cancer Res. 2022;12(10):4502–19.

[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36381328)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641399)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXmtFKktrY%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20inhibits%20tumor%20metastasis%20by%20regulating%20the%20Wnt%2F%CE%B2-catenin%2Fintegrin%20%CE%B21%2FFAK%20signaling%20pathway&journal=Am%20J%20Cancer%20Res&volume=12&issue=10&pages=4502-4519&publication_year=2022&author=Jiang%2CL)

12.   Juarez M, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol. 2020;85(6):1153–63.

[Article](https://link.springer.com/doi/10.1007/s00280-020-04041-z)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32474842)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtV2jsbbE)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Antitumor%20effects%20of%20ivermectin%20at%20clinically%20feasible%20concentrations%20support%20its%20clinical%20development%20as%20a%20repositioned%20cancer%20drug&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-020-04041-z&volume=85&issue=6&pages=1153-1163&publication_year=2020&author=Juarez%2CM)

13.   Zhang X, et al. Ivermectin augments the in vitro and in vivo efficacy of Cisplatin in Epithelial ovarian cancer by suppressing Akt/mTOR signaling. Am J Med Sci. 2020;359(2):123–9.

[Article](https://doi.org/10.1016%2Fj.amjms.2019.11.001)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32039764)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20augments%20the%20in%20vitro%20and%20in%20vivo%20efficacy%20of%20Cisplatin%20in%20Epithelial%20ovarian%20cancer%20by%20suppressing%20Akt%2FmTOR%20signaling&journal=Am%20J%20Med%20Sci&doi=10.1016%2Fj.amjms.2019.11.001&volume=359&issue=2&pages=123-129&publication_year=2020&author=Zhang%2CX)

14.   Nappi L, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020;130(2):699–714.

[Article](https://doi.org/10.1172%2FJCI130819)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31845908)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnvFSgt7k%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20inhibits%20HSP27%20and%20potentiates%20efficacy%20of%20oncogene%20targeting%20in%20tumor%20models&journal=J%20Clin%20Invest&doi=10.1172%2FJCI130819&volume=130&issue=2&pages=699-714&publication_year=2020&author=Nappi%2CL)

15.   Draganov D, et al. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021;7(1):22.

[Article](https://doi.org/10.1038%2Fs41523-021-00229-5)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33654071)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925581)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Gis7fO)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20converts%20cold%20tumors%20hot%20and%20synergizes%20with%20immune%20checkpoint%20blockade%20for%20treatment%20of%20breast%20cancer&journal=NPJ%20Breast%20Cancer&doi=10.1038%2Fs41523-021-00229-5&volume=7&issue=1&publication_year=2021&author=Draganov%2CD)

16.   Jawad MJ, Richardson A. Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells. Diseases. 2023;11(1):49. [https://doi.org/10.3390/diseases11010049](https://doi.org/10.3390/diseases11010049).

[Article](https://doi.org/10.3390%2Fdiseases11010049)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36975598)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047003)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXnsVSnsrY%3D)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivermectin%20augments%20the%20anti-cancer%20activity%20of%20pitavastatin%20in%20ovarian%20cancer%20cells&journal=Diseases.&doi=10.3390%2Fdiseases11010049&volume=11&issue=1&publication_year=2023&author=Jawad%2CMJ&author=Richardson%2CA)

17.   Jiménez-Gaona Y, et al. Outcome of Ivermectin in cancer treatment: an experience in Loja-Ecuador. Nurs Rep. 2023;13(1):315–26.

[Article](https://doi.org/10.3390%2Fnursrep13010030)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36976682)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054244)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Outcome%20of%20Ivermectin%20in%20cancer%20treatment%3A%20an%20experience%20in%20Loja-Ecuador&journal=Nurs%20Rep&doi=10.3390%2Fnursrep13010030&volume=13&issue=1&pages=315-326&publication_year=2023&author=Jim%C3%A9nez-Gaona%2CY)

18.   Yuan Yuan, et al. A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer. JCO. 2025;43:e13146–e13146. [https://doi.org/10.1200/JCO.2025.43.16_suppl.e13146](https://doi.org/10.1200/JCO.2025.43.16_suppl.e13146).

[Article](https://doi.org/10.1200%2FJCO.2025.43.16_suppl.e13146)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%2FII%20study%20evaluating%20the%20safety%20and%20efficacy%20of%20ivermectin%20in%20combination%20with%20balstilimab%20in%20patients%20with%20metastatic%20triple%20negative%20breast%20cancer&journal=JCO&doi=10.1200%2FJCO.2025.43.16_suppl.e13146&volume=43&pages=e13146-e13146&publication_year=2025&author=Yuan%2CYuan)

19.   Spreafico A, et al. The Future of Clinical Trial Design in Oncology. Cancer Discov. 2021;11(4):822–37.

[Article](https://doi.org/10.1158%2F2159-8290.CD-20-1301)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33811119)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099154)[CAS](http://link.springer.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlKqurnL)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20Future%20of%20Clinical%20Trial%20Design%20in%20Oncology&journal=Cancer%20Discov&doi=10.1158%2F2159-8290.CD-20-1301&volume=11&issue=4&pages=822-837&publication_year=2021&author=Spreafico%2CA)

20.   Buccheri S, et al. Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience. Trials. 2025;26(1):24.

[Article](https://link.springer.com/doi/10.1186/s13063-025-08724-x)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39833917)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749104)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Large%20simple%20randomized%20controlled%20trials-from%20drugs%20to%20medical%20devices%3A%20lessons%20from%20recent%20experience&journal=Trials&doi=10.1186%2Fs13063-025-08724-x&volume=26&issue=1&publication_year=2025&author=Buccheri%2CS)

21.   Nelson B, Faquin W. Researchers confront a rising tide of cancer misinformation: A fledgling field of research has documented major harms from misinformation on cancer treatment and prevention and is weighing how physicians can best counter the bad advice. Cancer Cytopathol. 2024;132(10):603–4.

[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39352248)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Researchers%20confront%20a%20rising%20tide%20of%20cancer%20misinformation%3A%20A%20fledgling%20field%20of%20research%20has%20documented%20major%20harms%20from%20misinformation%20on%20cancer%20treatment%20and%20prevention%20and%20is%20weighing%20how%20physicians%20can%20best%20counter%20the%20bad%20advice&journal=Cancer%20Cytopathol&volume=132&issue=10&pages=603-604&publication_year=2024&author=Nelson%2CB&author=Faquin%2CW)

22.   Gilene S, Haacker L, Rutan H, Pressey JG. The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient. Pediatr Blood Cancer. 2025;e31876. [https://doi.org/10.1002/pbc.31876](https://doi.org/10.1002/pbc.31876).

23.   Johnson SB, et al. Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. J Natl Cancer Inst. 2022;114(7):1036–9.

[Article](https://doi.org/10.1093%2Fjnci%2Fdjab141)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34291289)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer%20Misinformation%20and%20Harmful%20Information%20on%20Facebook%20and%20Other%20Social%20Media%3A%20A%20Brief%20Report&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdjab141&volume=114&issue=7&pages=1036-1039&publication_year=2022&author=Johnson%2CSB)

24.   Lancet. Health in the age of disinformation. Lancet. 2025;405(10474):173.

[Article](https://doi.org/10.1016%2FS0140-6736%2825%2900094-7)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Health%20in%20the%20age%20of%20disinformation&journal=Lancet.&doi=10.1016%2FS0140-6736%2825%2900094-7&volume=405&issue=10474&publication_year=2025)

25.   Stamm K, et al. Helping journalists get it right: a physicians’s guide to improving health care reporting. J Gen Intern Med. 2003;18(2):138–45.

[Article](https://doi.org/10.1046%2Fj.1525-1497.2003.20220.x)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12542589)[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494815)[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Helping%20journalists%20get%20it%20right%3A%20a%20physicians%E2%80%99s%20guide%20to%20improving%20health%20care%20reporting&journal=J%20Gen%20Intern%20Med&doi=10.1046%2Fj.1525-1497.2003.20220.x&volume=18&issue=2&pages=138-145&publication_year=2003&author=Stamm%2CK)

[Download references](https://citation-needed.springer.com/v2/references/10.1007/s11912-025-01704-z?format=refman&flavour=references)

## Funding

None.

## Author information

### Authors and Affiliations

1.   Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Regional Campus, Clearwater, FL, USA

Yash Patel,Jyotsna Chawla&Mayur S. Parmar

2.   Department of Foundational Sciences, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Regional Campus, Clearwater, FL, USA

Mayur S. Parmar

Authors

1.   Yash Patel
2.   Jyotsna Chawla
3.   Mayur S. Parmar

### Contributions

Funding: None. Ethics approval: Not applicable. Consent to participate: Not applicable. Written consent for publication: Not applicable. Code availability: Not applicable CRediT authorship contribution statement Y.P.: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Interpretation of data. J.C.: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Interpretation of data. M.S.P.: Writing – review & editing, Visualization, Validation, Methodology, Investigation, Formal analysis, Interpretation of data, Supervision, Conceptualization Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Data availability: Not applicable. Statement: To refine the final draft of the article, the author(s) utilized GenAI to assist in identifying and correcting grammatical errors and enhancing the overall readability of the final draft. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

### Corresponding author

Correspondence to [Mayur S. Parmar](mailto:mparmar@nova.edu).

## Ethics declarations

### Ethics Approval

Not applicable.

### Consent to Participate

Not applicable.

### Written Consent for Publication

Not applicable.

### Competing interest

The authors declare no competing interests.

### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

### Statement

To refine the final draft of the article, the author(s) utilized GenAI to assist in identifying and correcting grammatical errors and enhancing the overall readability of the final draft. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

## Additional information

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

[Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Ivermectin%20in%20Cancer%20Treatment%3A%20Should%20Healthcare%20Providers%20Caution%20or%20Explore%20Its%20Therapeutic%20Potential%3F&author=Yash%20Patel%20et%20al&contentID=10.1007%2Fs11912-025-01704-z&copyright=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Science%2BBusiness%20Media%2C%20LLC%2C%20part%20of%20Springer%20Nature&publication=1534-6269&publicationDate=2025-07-26&publisherName=SpringerNature&orderBeanReset=true)

## About this article

[![Image 5: Check for updates. Verify currency and authenticity via CrossMark](blob:http://localhost/df43c82f6cb6dcd2a87db38f317bf9f2)](https://crossmark.crossref.org/dialog/?doi=10.1007/s11912-025-01704-z)

### Cite this article

Patel, Y., Chawla, J. & Parmar, M.S. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?. _Curr Oncol Rep_**27**, 1070–1079 (2025). https://doi.org/10.1007/s11912-025-01704-z

[Download citation](https://citation-needed.springer.com/v2/references/10.1007/s11912-025-01704-z?format=refman&flavour=citation)

*   Accepted: 30 June 2025

*   Published: 26 July 2025

*   Version of record: 26 July 2025

*   Issue date: September 2025

*   DOI: https://doi.org/10.1007/s11912-025-01704-z

### Keywords